chang price
navihealth grew dd quarter
driven grow demand solid execut
manag expect medic segment om trend
without inclus inventori step cost saw
base result januari price increas brand inflat
track in-lin expect
medic segment neg impact commod price
suppli disrupt exam glove compani expect growth
flat remaind year ex patient recoveri
primarili due headwind exam glove also softer
expect profit cordi
pharmaceut segment profit quarter decreas driven
cost relat on-going invest platform well
net perform gener program
thesi updat still somewhat conflict post
would character line better expect
least vs st howev cant help bit concern
develop medic busi certain
stock cheap nearli everi metric ex ebitda given
leverag also feel confid pharma perform reason
well specialti remain notabl outperform real conflict
feel tie back medic unsur
diverg trend play near medium term view
long-term strategi highli sensibl seem
invest need make vision realiti possibl
first contempl furthermor competit forc portion
busi also seem pressur price share inevit
profit although hard fulli teas magnitud thu
view debat remain whether remain cheap stock
get level clariti path updat
forecast reason st concern us albeit
possibl come clariti somewhat
tax rate path all-in given factor understand bull
argument acknowledg valuat prefer evid
path medic prior turn bullish thu reiter
line rate rais pt modestli
continu next page
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
 rais midpoint tax reform
gener brand price
gener inflat msd deflat
 track slightli better drive upsid pharma
 specialti nuclear continu perform better expect
 rfp larg account renew larg one dont renew end
brand inflat
 less brand margin conting inflat
jon giacomin veteran
patient recoveri busi accret integr cardin health brand product
 exclud patient recoveri medic segment flat driven cordi exam glove
significantli reduc portion va contract full effect began
reinstat medic devic tax
 cordi busi well asia pacif china good turnaround japan growth korea
australia new zealand amea
 patient recoveri track sale expect
fx forecast littl bit tailwind balanc year signific driver
complet tax reform impact may requir adjust futur period
reflect benefit lower blend feder tax rate
blend statutori sale tax rate
 effect tax rate includ feder tax tax state etc
net-net expect see lower
look cash benefit tax reform proce china divestur
commit deploy capit balanc way organ growth dividend valuing-cr share repo
chang
cardin health stat million except per share data fy end june organ gp growth revenu margin growth revenu ep share net incom price-to-earnings premium/discount isi healthcar technolog distribut februari
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
laboratori corp america hold
articl articl
time dissemin februari et
analyst ross muken elizabeth anderson suzi yoon primarili respons prepar research report attest
follow view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view
